| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/486983/2011 (23.6.11) |
| Publication Date | 23/06/2011 |
| Content Type | News |
|
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in June 2011, concluded that the benefits of systemic nimesulide-containing medicines continued to outweigh their risks in the treatment of patients with acute pain and primary dysmenorrhoea. However, the Agency advised that these medicines should no longer be used for the symptomatic treatment of osteoarthritis. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/06/news_detail_001285.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=true |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
